Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Merck Sharp & Dohme LLC
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07286149CT.gov A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) | — | Recruiting | — | — | — |
NCT06067776CT.gov Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer | — | Not Yet Recruiting | — | — | — |
NCT05786924CT.gov Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | — | Recruiting | — | — | — |
NCT04648189CT.gov Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC | — | Withdrawn | — | — | — |
NCT01109524CT.gov Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT01184482CT.gov Lapatinib and Cetuximab in Patients With Solid Tumors | — | Completed | — | — | — |
NCT01059188CT.gov Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00998101CT.gov Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy | — | Withdrawn | — | — | — |
NCT00673738CT.gov Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC) | — | Completed | — | — | — |
NCT00533949CT.gov High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery | — | Completed | — | — | — |
Show 10 more trialsShow fewer
NCT00519831CT.gov Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC | — | Terminated | — | — | — |
NCT00408499CT.gov Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00288054CT.gov S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT00124618CT.gov Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00622674CT.gov Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00103207CT.gov Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer | — | Completed | — | — | — |
NCT00117962CT.gov Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00193453CT.gov Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00085501CT.gov S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00081302CT.gov Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cetuximab (this asset) | Merck Sharp & Dohme LLC | P3 | B · 62 |
| Cis-Diamminedichloroplatinum Ii | University of Vermont | P4 | BB |
| Carboplatin | SystImmune Inc. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Etoposide | SystImmune Inc. | P3 | BB |
| Nivolumab | University of Chicago | P4 | BB |
| Propofol | Kaohsiung Medical University Chung-Ho Memorial Hospital | P4 | BB |
| Vinorelbine Ditartrate | Alliance for Clinical Trials in Oncology | P3 | BB |
| Vinblastine | Intensity Therapeutics, Inc. | P3 | BB |
+42 more in the Lung Cancer cohort
Other indications for Cetuximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colon Adenocarcinoma | — | P3 | BB · 70 |
| Rectal Carcinoma | — | P2 | BB · 69 |
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cetuximab in Lung Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cetuximab-lung-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →